Adenosquamous carcinoma of the lung
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
| Adenosquamous carcinoma of the lung | |
|---|---|
| Diagnosis in short | |
 Adenosquamous carcinoma of lung. H&E stain. | |
| LM DDx | squamous cell carcinoma of the lung, adenocarcinoma of the lung |
| Site | lung - see lung tumours |
|
| |
| Prevalence | rare |
| Clin. DDx | other lung tumours |
Adenosquamous carcinoma of the lung, also lung adenosquamous carcinoma, is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.
It is grouped with the non-small cell lung cancers.
General
- Rare.
- Respond to tyrosine kinase inhibitors.[1][2]
Microscopic
- Adenocarcinoma component (>=10% of tumour ‡).
- Squamous cell carcinoma component (>=10% of tumour ‡).
Note:
- ‡ Criteria used by individual pathologists may vary and/or may not be uniformly applied.[3]
DDx:
- Squamous cell carcinoma of the lung.
- Adenocarcinoma of the lung.
- Metastatic adenosquamous carcinoma - requires history.
Images
ASC - intermed. mag. (WC)
ASC - intermed. mag. (WC)
ASC - high mag. (WC)
ASC - very high mag. (WC)
www
- Lung adenosquamous carcinoma (webpathology.com).
- Lung adenosquamous carcinoma (flickr.com/Yale Rosen).
Sign out
Biopsy - possible adenosquamous carcinoma
Left Upper Lobe of Lung, Core Biopsy:
- NONSMALL CELL CARCINOMA, FAVOUR ADENOCARCINOMA, CANNOT EXCLUDE ADENOSQUAMOUS CARCINOMA.
Comment:
The tumour stains as follow:
POSITIVE: TTF-1, CK5/6 (focal), p63, napsin A.
NEGATIVE: (none).
The positive staining (TTF-1 and napsin A versus CK5/6 and p63) appears to be in different tumour cells.
The case was reviewed internally and there is agreement on the above interpretation.
Note:
- Cases should not be signed as adenosquamous carcinoma on biopsy, due to the percentage requirements (>=10% for both components) - see microscopic section.
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.
- ↑ 3.0 3.1 Rao, N. (Jul 2014). "Adenosquamous carcinoma.". Semin Diagn Pathol 31 (4): 271-7. doi:10.1053/j.semdp.2014.06.004. PMID 25002356.
- ↑ Vassella E, Langsch S, Dettmer MS, Schlup C, Neuenschwander M, Frattini M, Gugger M, Schäfer SC (September 2015). "Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?". Oncotarget 6 (27): 23905–16. doi:10.18632/oncotarget.4163. PMC 4695160. PMID 26068980. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695160/.